combat nausea from semaglutide Managing on Semaglutide: Evidence-Based Relief 10 tips to help manage

You can review the FDA prescribing information for those products for details on approved uses, dosing, and risks

Abstract The glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) are members of the secretin-like class B family of G-protein-coupled receptors (GPCRs) and have opposing physiological roles in insulin release and glucose homeostasis 1

In September 2025, the FDA issued a series of warning letters to online sellers of compounded GLP-1 medications, and in February 2026, Novo Nordisk filed suit against Hims & Hers, alleging patent infringement through compounded semaglutide products

Patients with inflammatory bowel disease considering semaglutide therapy should engage in comprehensive discussions with their healthcare team, ideally involving both their gastroenterologist and the physician prescribing the medication